Atara Biotherapeutics To Present Clinical Data in Epstein-Barr Virus-Driven (EBV+) Acquired & Primary Immunodeficiency Lymphoproliferative Diseases (AID-LPD and PID-LPD) from Tab-Cel® Expanded Access Program in e-Poster at ESMO 2020 Virtual Congress

Atara Biotherapeutics Announces All Progressive Multiple Sclerosis Patients with Sustained Disability Improvement at Six Months Confirmed Improvement at 12 Months in the Phase 1a Study of ATA188

ECTRIMS 2020 Investor Presentation

Investor Presentation

European Society for Medical Oncology (ESMO) 2020 Virtual Congress

Sep 17 – Sep 21, 2020

Conference Call and Webcast to Review MS Data Presentation

Sep 11, 2020 • 8:30 am EDT